Conference Reports for NATAP

Back

HIV Drug Therapy Glasgow 2024 10-13 November     Evaluation of T-cell immunosenescence markers in virologically suppressed people living with HIV aged over 60 years on BIC/FTC/TAF or DTG/3TC: the Collateral study - (11/18/24)   VIROLOGICAL EFFICACY OF DOLUTEGRAVIR PLUS DARUNAVIR IN MULTI-DRUG-RESISTANT HIV PATIENTS: A REAL-WORLD COHORT STUDY WITH DATA FROM THE PRESTIGIO REGISTRY - (11/18/24)   Long-term efficacy and safety of dolutegravir/ lamivudine in virologically suppressed persons with HIV and history of resistance to lamivudine: week 96 results of VOLVER clinical trial - GESIDA 11820 - (11/18/24)   Efficacy of dolutegravir plus lamivudine in treatment-naïve people living with HIV without baseline drug-resistance testing available: 48-week results from the randomized D2ARLING study - (11/18/24)   Doravirine plus raltegravir (DOR/RAL) two-drug regimen as a maintenance ART in virally suppressed PWH: results of the international randomised DORAL trial - (11/18/24)   Long-term outcomes following liver transplantation (LT) in patients with HIV (PWH): a retrospective single-centre case-control study - (11/18/24)   Acute/Recent Infections and Reinfections by HCV in MSM with and without HIV in the Region of Madrid (ATHENS Study) - (11/18/24)   Prevalence Trends of Active HCV Infection Among People with HIV in Spain (2002-2023): Nearing Elimination - (11/18/24)   Kidney Transplant HIV+ Donor to Positive Recipient - Should be SOC - (11/17/24)   Comparison of 4 Frailty scores to predict adverse health outcomes and mortalit yin people living with HIV aged 70 years and more (ANRS EP66 SEPTAVIH study) - (11/17/24)   Acceptability and feasibility of digital assessment of falls risk, frailty and mobility impairment using wearable sensors in PLWH as part of HIV care - (11/17/24)   Antiretroviral therapy, comorbidities and concomitant medication in people with HIV aged over 75 years in one centre in London, UK - (11/17/24)   Long-term change of renal function among people with HIV who received tenofovir alafenamide (TAF)-containing ART - (11/17/24)   poster - Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study - (11/17/24)   Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real- world OncoVIHAC ANRS CO24 cohort study - (11/17/24)   Randomized, multicenter, double-blind clinical trial designed to evaluate the safety and convenience of switching from dolutegravir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV, good virologic control and neuropsychiatric comorbidities: Week 24 results from the GESIDA 11920 - MIND Study. - (11/17/24)   Depression (20%) and anxiety (15%) symptoms among people with HIV in the UK: prevalence, correlates and treatment. Results from the Positive Voices 2022 study - (11/17/24)   Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Naïve People With Both HIV-1 and Hepatitis B: 3-Year Outcomes From ALLIANCE - (11/16/24)   LEN PrEP PURPOSE-2 Twice-Yearly Gilead Glasgow Press Release - (11/16/24)   PrEP-Associated Stigma in Europe: Findings From a Real-World Survey - (11/16/24)   Cost-effectiveness and Public-Health Impact of Cabotegravir Long-Acting Injectable for HIV Pre-exposure Prophylaxis in Canada - (11/16/24)   PURPOSE 1 LEN PrEP Summary - (11/16/24)   Len LA PrEP PURPOSE 2 Summary - (11/16/24)   Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2) - (11/16/24)   Annual persistence in use of twice-yearly lenacapavir versus daily oral PrEP in the PURPOSE 1 phase 3 trial - (11/16/24)   Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirin - (11/15/24)   Once-weekly islatravir plus lenacapavir in virologically suppressed PWH: Week 48 safety, efficacy, and metabolic changes - (11/15/24)   Treatment-Emergent Integrase Strand Transfer Inhibitor (INSTI) Resistance-Associated Mutations Among People Living With HIV-1 Treated With Dolutegravir (DTG) + Lamivudine (3TC) With Pre-existing M184V/I From Real-world and Interventional Studies - (11/15/24)   Real-world Experience of DTG + 3TC Regimen: Results From the French Dat'AIDS Cohort (2015-2022) - (11/15/24)   Similar Virologic Outcomes and Frequency of Isolated Viremic Events (Blips, Low-Level Viremia and Suspected Virologic Failure) Between Oral and Long-acting Antiretroviral Therapy: A Pooled Analysis of Phase 3/3b Cabotegravir + Rilpivirine Long-Acting Studies - (11/15/24)   Real-World Utilization of Cabotegravir/Rilpivirine: An Observational Analysis of Adherence and Persistence using a Patient Support Program in Canada, Preliminary Results - (11/15/24)   Reduction in estimated Glomerular Filtration Rate (eGFR) Observed With Doravirine (DOR) is Caused by Inhibition of Organic Cation Transporter 2 (OCT2) - (11/15/24)   HIV Pipeline, Daily, Oral, LA. New Treatments and Future Combinations - (11/15/24)   2nd generation INSTI resistance in randomized trials and cohorts - (11/15/24)   INSTI resistance global data trends - (11/15/24)   Clinical features and resistance patterns during second-generation InSTI failure: The ROSETTA-registry - (11/15/24)   Safety and Immunogenicity of GS-1966+GS-1144 Vaccines in Virally Suppressed Adults Living With HIV-1: A Phase 1b, Randomized, Placebo-Controlled Study - (11/15/24)   Metabolic Changes at 48 Weeks in Virologically Suppressed People With HIV Switching From Complex Antiretroviral Regimens to Bictegravir Plus Lenacapavir: ARTISTRY-1 Trial - (11/15/24)   Risk of Hypertension in Treatment-Naïve People With HIV in the US Receiving INSTI Versus NNRTI, or TAF- Versus Non-TAF-Based Regimens: Pooled Analysis of Blood Pressure Data From Five Clinical Trials - (11/15/24)   Replication-Competent HIV-1 Harboring Resistance-Associated Mutations is Present in the Viral Reservoir - (11/15/24)   Four-Year Outcomes From the BICSTaR Study: Observational Analysis of B/F/TAF in Treatment-Naïve and Treatment-Experienced People With HIV in Canada, France, and Germany - (11/15/24)   Comparison of Treatment-emergent Resistance-associated Mutations Among Single-tablet Regimens and Cabotegravir + Rilpivirine for the Treatment of Virologically Suppressed People With HIV: A Systematic Literature Review and Network Meta-analysis - (11/14/24)   Comparison of Treatment-emergent Resistance-associated Mutations Among Single-tablet Regimens and Cabotegravir + Rilpivirine for the Treatment of Virologically Suppressed People With HIV: A Systematic Literature Review and Network Meta-analysis - Supplementary Materials - (11/14/24)   Long-acting treatment for non-virally suppressed individuals: real world evidence - (11/14/24)   Efficacy and Safety Analysis of Lenacapavir With Broadly Neutralising Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Highly Sensitive to One or Both Broadly Neutralising Antibodies - (11/14/24)   Pharmacokinetics of oral islatravir plus lenacapavir given once weekly in an open-label, active-controlled, phase 2 study of virologically suppressed people living with HIV-1 - (11/14/24)   Once-weekly islatravir plus lenacapavir in virologically suppressed PWH: Week 48 safety, efficacy, and metabolic changes - (11/14/24)   Post-exposure prophylaxis with doxycycline (doxyPEP) in a cohort of men who have sex with men (MSM) in high risk for sexually transmitted infections (STI). The PRIDOX study - (11/14/24)   A provider's perspective of doxyPEP, Community Thoughts - (11/14/24)   ViiV HEALTHCARE ANNOUNCES DATA DEMONSTRATING DOVATO (DTG/3TC) IS HIGHLY EFFECTIVE IN TREATMENT-NAIVE PEOPLE WITH ADVANCED HIV - (11/14/24)   Comparable efficacy and safety of dolutegravir/ lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: The DOLCE study. - (11/14/24)   New treatments and future combinations - (11/11/24)   Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic - (11/06/24)   ViiV HEALTHCARE EXPANDS ON REAL-WORLD DATA SUPPORTING USE OF LONG-ACTING THERAPIES IN DIVERSE PATIENT POPULATIONS AT HIV GLASGOW - (11/06/24)